Premium
Insight into newly discovered innate immune modulation in atopic dermatitis
Author(s) -
Park Chang Ook,
Noh Seongmin,
Jin Shan,
Lee Na Ra,
Lee Yun Sun,
Lee Hemin,
Lee Jungsoo,
Lee Kwang Hoon
Publication year - 2013
Publication title -
experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.108
H-Index - 96
eISSN - 1600-0625
pISSN - 0906-6705
DOI - 10.1111/exd.12034
Subject(s) - innate lymphoid cell , innate immune system , thymic stromal lymphopoietin , immunology , immune system , acquired immune system , ccl18 , biology , pattern recognition receptor , cytokine , inflammation , classical complement pathway , interleukin 33 , interleukin , complement system
Atopic dermatitis ( AD ) is a highly pruritic, chronic relapsing inflammatory skin disease characterized by innate and adaptive immune reactions. In AD , innate immune mechanisms such as pattern recognition receptors and antimicrobial peptides have been investigated in detail, but recently, epidermis‐derived cytokines, namely thymic stromal lymphopoietin ( TSLP ), IL ‐25 and IL ‐33, were shown to participate in innate immune reactions independently of adaptive immunity. In addition to conventional innate cells, such as mast cells, basophils and eosinophils, T h2 cytokine‐producing invariant natural killer T (i NKT ) cells, innate lymphoid cells ( ILC s) and T h17/ T h22 cytokine‐producing innate cells – i NKT cells and natural killer ( NK )‐like cells – can participate in innate immune modulation in AD . Accordingly, early control of innate immune responses in AD before activation of adaptive immune responses by conventional T and B cells that perpetuate chronic skin inflammation may adequately alleviate acute exacerbations of AD . Therefore, we hypothesized that select immune modulators targeting the innate immune response could potentially be used for individualized treatment of AD .